Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China

被引:0
|
作者
Shi, Yin [1 ,2 ,3 ]
Xiao, Di [1 ,2 ,3 ]
Li, Shuishi [2 ,4 ]
Liu, Shao [1 ,2 ,3 ]
Zhang, Yu [5 ,6 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Pharm, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China
[3] Hunan Inst Pharm Practice & Clin Res, Changsha, Peoples R China
[4] Cent South Univ, Xiangya Hosp, Dept Gen Surg, Changsha, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Gynecol, Changsha, Peoples R China
[6] Gynecol Oncol Res & Engn Ctr Hunan Prov, Changsha, Peoples R China
基金
中国国家自然科学基金;
关键词
niraparib; routine surveillance; ovarian cancer; maintenance therapy; cost-effectiveness; THERAPY;
D O I
10.3389/fphar.2023.1198585
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Niraparib improved survival in platinum-sensitive recurrent ovarian cancer (PSROC) patients versus routine surveillance, accompanied by increased costs. Based on the NORA trial, we evaluated for the first time the cost-effectiveness of maintenance niraparib with individualized starting dosage (ISD) in China.Methods: A Markov model was developed to simulate the costs and health outcomes of each strategy. The total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were measured. One-way and probabilistic sensitivity analysis were performed to estimate model robustness. Scenario analyses were also conducted.Results: Compared to routine surveillance, niraparib additionally increased QALYs by 0.59 and 0.30 in populations with and without germline BRCA (gBRCA) mutations, with incremental costs of $10,860.79 and $12,098.54, respectively. The ICERs of niraparib over routine surveillance were $18,653.67/QALY and $39,212.99/QALY. At a willingness-to-pay (WTP) threshold of $37,488/QALY, the ISD enhanced the likelihood of cost-effectiveness from 9.35% to 30.73% in the gBRCA-mutated group and from 0.77% to 11.74% in the non-gBRCA mutated population. The probability of niraparib being cost-effective in the region with the highest per capita Gross Domestic Product (GDP) in China was 74.23% and 76.10% in the gBRCA-mutated and non-gBRCA mutated population, respectively. Niraparib was 100% cost-effective for National Basic Medical Insurance beneficiaries under the above WTP thresholds.Conclusion: Compared to routine surveillance, the ISD of niraparib for maintenance treatment of PSROC is cost-effective in the gBRCA-mutated population and more effective but costly in the non-gBRCA mutated patients. The optimized niraparib price, economic status, and health insurance coverage may benefit the economic outcome.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Cost-effectiveness of maintenance niraparib with an individualized starting dosage compared to routine surveillance in patients with platinum-sensitive recurrent ovarian cancer in China
    Shi, Yin
    Xiao, Di
    Li, Shuishi
    Liu, Shao
    Zhang, Yu
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A74 - A76
  • [2] Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
    Zhong, Lixian
    Anh Thu Tran
    Tomasino, Taylor
    Nugent, Elizabeth
    Smith, Judith A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (12): : 1219 - 1228
  • [3] Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer
    Qiu, Yijin
    Zha, Jingkai
    Ma, Aixia
    Zhou, Ting
    GYNECOLOGIC ONCOLOGY, 2023, 174 : 175 - 181
  • [4] Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer
    Leung, John Hang
    Lang, Hui-Chu
    Wang, Shyh-Yau
    Lo, Hsueh Fang
    Chan, Agnes L. F.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (03) : 489 - 496
  • [5] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
    Mirza, M. R.
    Monk, B. J.
    Herrstedt, J.
    Oza, A. M.
    Mahner, S.
    Redondo, A.
    Fabbro, M.
    Ledermann, J. A.
    Lorusso, D.
    Vergote, I.
    Ben-Baruch, N. E.
    Marth, C.
    Madry, R.
    Christensen, R. D.
    Berek, J. S.
    Dorum, A.
    Tinker, A. V.
    du Bois, A.
    Gonzalez-Martin, A.
    Follana, P.
    Benigno, B.
    Rosenberg, P.
    Gilbert, L.
    Rimel, B. J.
    Buscema, J.
    Balser, J. P.
    Agarwal, S.
    Matulonis, U. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2154 - 2164
  • [6] COST-EFFECTIVENESS OF NIRAPARIB AND OLAPARIB AS MAINTENANCE THERAPY FOR PATIENTS WITH PLATINUM SENSITIVE< RECURRENT OVARIAN CANCER
    Zhong, L.
    Tran, A. T.
    Tomasino, T.
    Smith, J. A.
    Nugent, E. K.
    VALUE IN HEALTH, 2018, 21 : S29 - S29
  • [7] PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
    Smith, Haller J.
    Haygood, Christen L. Walters
    Arend, Rebecca C.
    Leath, Charles A., III
    Straughn, Michael, Jr.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 59 - 62
  • [8] Management of platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
    Havrilesky, Laura J.
    Secord, Angeles Alvarez
    Kulasingam, Shalini
    Myers, Evan
    GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 211 - 218
  • [9] A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer
    Case, Ashley S.
    Rocconi, Rodney P.
    Partridge, Edward E.
    Straughn, J. Michael, Jr.
    GYNECOLOGIC ONCOLOGY, 2007, 105 (01) : 223 - 227